Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 19, 2024
Daily News
September 19, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
- Keidanren Calls for Review of Japan's Unique Pharmaceutical Regulations
September 19, 2024
- Viatris to Discontinue Nesp Biosimilar after Global Business Sell-Off
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
- AnGes’s Gene Therapy Collategene Gets FDA Breakthrough Therapy Tag
September 19, 2024
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- J-TEC Prepping to File for Allogeneic Cultured Epidermis, Eyes Overseas Export
September 19, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…